{
  "@context": "aku-v2",
  "@type": "clinical-guideline",
  "@id": "vasc:fmd:family-screening",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:17:00.000Z",
    "updated": "2026-01-07T03:17:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.88,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-disorders",
    "type": "screening-protocol",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "FMD Family Screening",
    "description": "Screening recommendations for first-degree relatives of patients with fibromuscular dysplasia",
    "key_concepts": [
      {
        "concept": "Familial FMD",
        "details": "Approximately 7-11% of FMD patients have affected first-degree relatives"
      },
      {
        "concept": "Screening Recommendation",
        "details": "Consider screening first-degree relatives, especially if severe presentation or aneurysm"
      },
      {
        "concept": "Screening Modality",
        "details": "Noninvasive imaging (CTA or MRA) from brain to pelvis preferred"
      },
      {
        "concept": "Age to Screen",
        "details": "No consensus; may begin screening in young adulthood if family history significant"
      }
    ],
    "clinical_significance": "Early detection may prevent complications in asymptomatic family members"
  },
  "provenance": {
    "primary_sources": ["Kiando SR et al. J Am Coll Cardiol 2016"]
  }
}
